Elegen Reduces Pricing for ENFINIA™ DNA, Expanding Access to Advanced Cell-Free DNA Manufacturing
Elegen, a leader in next-generation cell-free DNA manufacturing, has announced a 25% reduction in the pricing of its ENFINIA™ DNA products. This move makes high-quality, long, complex, NGS-verified DNA more accessible to researchers, biotech innovators, and companies developing cutting-edge therapeutics. The price cut applies to both linear and plasmid ENFINIA™ DNA products, accommodating a wide range of standard and complex sequence designs.
Unlocking Greater Access Through Advanced Technology
The price reduction is a direct result of efficiency gains made possible by it’s advanced cell-free cloning technology and the company’s new state-of-the-art facility. The integration of automation and machine learning has significantly improved synthesis success rates, enabling the company to deliver high-quality DNA faster and at a lower cost. With these advancements, Elegen can now produce long and complex DNA in as little as 6 to 8 days, with pricing starting as low as $0.15 per base pair. Additionally, customers can access further discounts for bulk orders.
“We fully expected to lower our pricing as our customer base grew and as we streamlined efficiencies in our technology platform,” said Mark Lasinski, Senior Vice President of Sales and Marketing at Elegen. “As we continue to invest in automation and process optimization, we’re able to innovate more quickly, reduce our cost of goods, and pass those savings along to our customers. This helps researchers screen and optimize long, complex constructs more efficiently, ultimately speeding up candidate selection and advancing development timelines.”
Revolutionizing DNA Manufacturing with ENFINIA™ DNA
ENFINIA™ DNA is uniquely produced using a cell-free system, overcoming the limitations commonly faced by conventional cell-based cloning methods. By utilizing a cell-free process, Elegen can produce DNA with industry-leading lengths—up to 7 kb for linear DNA and 18 kb for plasmid DNA—without compromising on complexity. Furthermore, each construct is verified through Next-Generation Sequencing (NGS) to ensure precision, making it ready for immediate use in customer workflows.
This approach delivers several advantages over traditional methods, including faster turnaround times and greater flexibility in handling more complex DNA sequences. The ability to produce high-quality, long DNA quickly is essential for many applications, including gene and cell therapy, synthetic biology, and mRNA vaccine development.
Introducing ENFINIA™ Plasmid DNA for Faster Clonal Synthesis
Earlier this year, Elegen introduced ENFINIA™ Plasmid DNA, a faster and cost-effective solution for clonal synthesis of long, complex genes. This offering allows researchers to access high-complexity plasmid genes up to 15 kb in length. Like ENFINIA™ DNA, ENFINIA™ Plasmid DNA is NGS-verified and can be shipped globally from Elegen’s U.S.-based facilities in as few as 10 business days. This product offers significant benefits to customers who require rapid access to complex gene sequences for their research or therapeutic applications.
Empowering Innovation in Synthetic Biology and Therapeutics
The pricing update is part of Elegen’s ongoing commitment to driving innovation in several key areas, including synthetic biology, gene and cell therapy, and mRNA vaccine development. By reducing the cost of high-quality DNA and improving production timelines, Elegen empowers researchers with an unconstrained supply of DNA, enabling them to accelerate discoveries and bring novel therapeutics to market more quickly.
This update also underscores the company’s broader mission to make cutting-edge biotechnological solutions more accessible to a global network of researchers and innovators. As the demand for synthetic biology solutions continues to grow, Elegen’s ability to offer affordable, reliable, and fast DNA manufacturing positions the company as a key player in the rapidly expanding biotech landscape.
Elegen Reduces Pricing for ENFINIA™ DNA, Expanding Access to Advanced Cell-Free DNA Manufacturing
A Game-Changer for Biotech and Beyond
Elegen’s continued investment in advanced manufacturing technologies and its innovative approach to DNA synthesis are changing the game for researchers in a variety of fields. The price reduction for ENFINIA™ DNA further reinforces the company’s position at the forefront of next-generation DNA manufacturing, offering researchers the tools they need to push the boundaries of discovery in synthetic biology, gene therapy, and more.
As the biotech industry moves towards faster, more efficient, and scalable solutions, Elegen is leading the way by making high-quality, complex DNA accessible to everyone from startups to global pharmaceutical companies. With the latest pricing update, Elegen continues to ensure that the next generation of scientific breakthroughs is powered by the best tools available.
For more information on ENFINIA DNA and updated pricing, visit ecommerce.elegen.com.
About Elegen
Elegen is bringing unique insights and technical innovation to create high-quality synthetic DNA faster, catalyzing the next revolution in the life sciences. The company is led by seasoned leaders with decades of experience developing novel and scalable approaches in molecular biology, chemistry and microfluidics. Elegen uses a proprietary microfluidics approach to build longer, higher-quality DNA on a faster timeline for agricultural, chemical, healthcare and pharma industries. Founded in 2017, Elegen is privately held and based in the San Francisco Bay Area. For more information, visit elegenbio.com and connect with us on LinkedIn and X (Twitter).
